10-Q: OS Therapies Reports Q1 2026 Results, Focus on Regulatory Submissions

OS Therapies Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and continued net losses, while advancing its OST-HER2 therapy towards regulatory submissions.

Summary

• OS Therapies Inc. reported a net loss of $10.4 million for the three months ended March 31, 2026, compared to a net loss of $3.9 million for the same period in 2025.
• Research and development expenses increased significantly to $7.4 million from $1.3 million, primarily due to costs associated with the Phase IIb clinical trial for OST-HER2.
• General and administrative expenses decreased to $2.8 million from $3.7 million.
• The company had $917,552 in cash and cash equivalents as of March 31, 2026.
• Significant financing activities occurred, including a $2.0 million Bridge Financing and a $3.4 million warrant exercise inducement offering in Q1 2026.
• Subsequent to the quarter, on April 2, 2026, the company completed a registered direct offering raising approximately $4.7 million and converting its Bridge Convertible Notes.
• The company is preparing for regulatory submissions for OST-HER2, with anticipated Type B meeting with the FDA in Q2 2026 and conditional Marketing Authorization Application submissions to MHRA and EMA in Q2 2026.
• Confirmatory clinical studies are expected to initiate in Q3 2026.
• The company has $7.3 million in accounts payable and accrued expenses related to consulting fees and VAT as of March 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant increase in net loss and R&D expenses, coupled with the ongoing going concern uncertainty, despite positive clinical trial data and upcoming regulatory milestones.

Positives

• Positive immune biomarker data from the Phase IIb trial for OST-HER2 was announced in January 2026, indicating a correlation between interferon gamma pathway activation and overall survival.
• The company is progressing towards regulatory submissions for OST-HER2, with anticipated submissions to the FDA, MHRA, and EMA in Q2 2026.
• Financing activities in Q1 2026 and subsequent to the quarter provided significant capital, with approximately $4.7 million raised in the April 2, 2026 registered direct offering.
• The company believes its current cash and proceeds from recent financing will be sufficient to fund operations for at least the next twelve months.
• The Phase IIb clinical trial for OST-HER2 achieved its primary endpoint with statistical significance in Q1 2025, and final two-year overall survival data showed 75% survival in treated patients compared to 40% in historical controls.

Negatives

• The company reported a net loss of $10.4 million for the three months ended March 31, 2026, and an accumulated deficit of $77.6 million.
• Cash and cash equivalents stood at $917,552 as of March 31, 2026, which management notes is insufficient to fund operations without additional capital.
• Research and development expenses increased substantially by $6.1 million year-over-year, impacting the net loss.
• The company has significant liabilities, including $15.2 million in accounts payable and accrued expenses and $1.3 million in convertible notes as of March 31, 2026.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company expects vendor and related costs associated with regulatory approval efforts to total approximately $20.0 million and continue into the remainder of 2026.
• Sales of a substantial number of shares of common stock could cause the market price to decline and make it more difficult to raise future capital.
• The company is subject to risks associated with clinical trials, regulatory approvals, and the commercialization of its product candidates.
• The company has experienced significant net losses and negative cash flows from operations since inception.

Future Outlook

The company anticipates submitting clinical Biologics License Application (BLA) modules following an expected Type B meeting with the FDA in the second quarter of 2026 and completing conditional Marketing Authorization Application (MAA) submissions to the MHRA and EMA in the second quarter of 2026. Additional biomarker data is expected in Q2 2026. Confirmatory clinical studies are expected to initiate in Q3 2026. The company expects research and development expenses to increase substantially as it advances OST-HER2 and OST-tADC into clinical development. General and administrative expenses are also expected to increase to support continued research and development activities.

Management Comments

• Management has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.
• The Company's current cash balance is insufficient to fund operations.
• The Company is actively seeking additional capital through public or private equity offerings or debt financings. However, there can be no assurance that the Company will be successful in sequestering additional financing on favorable terms, or at all.
• Management believes that the net proceeds from recent transactions, together with existing cash, will be sufficient to fund operating expenses and capital expenditures for at least the next twelve months.

Industry Context

StockSavvy.ai notes that OS Therapies is operating in the highly competitive and capital-intensive biopharmaceutical sector, focusing on rare pediatric diseases like Osteosarcoma. The company's strategy of advancing its lead candidate, OST-HER2, through regulatory pathways and exploring potential applications in other solid tumors is a common approach in the industry. The significant increase in R&D spending reflects the typical cost structure of drug development, while the reliance on external financing highlights the inherent risks and funding challenges faced by early-stage biopharma companies.

Comparison to Industry Standards

• The net loss of $10.4 million for the quarter is substantial, but not unusual for a clinical-stage biopharmaceutical company investing heavily in R&D. For comparison, companies like Moderna and BioNTech also reported significant losses in their early development stages.
• The increase in R&D expenses to $7.4 million is a substantial portion of the company's operating expenses, aligning with industry standards where R&D typically constitutes the largest cost center for drug developers.
• The company's cash burn rate of approximately $4.6 million per quarter for operating activities is a critical metric. Companies in this space often require substantial cash reserves to fund trials through to approval. For instance, companies like Vertex Pharmaceuticals, despite being more mature, still invest billions annually in R&D.
• The reliance on equity and debt financing, including recent offerings and warrant exercises, is a standard practice for biopharmaceutical companies to fund their operations and development pipelines, as seen with numerous biotech IPOs and follow-on offerings.

Legal Proceedings

• The company was involved in an arbitration hearing related to a claim by its former investment advisor concerning underwriter compensation for its IPO and subsequent equity offerings. The arbitrators awarded the former investment advisor $1,055,428 and their attorneys $308,805, totaling $1,379,361, which has been accrued.
• The company is not currently a party to any other pending or threatened legal proceedings that could have a material adverse effect on its results of operations or financial position.

Related Party Transactions

• As of March 31, 2026, the Company had no payroll payable to the CEO, compared to $36,792 as of December 31, 2025.
• As of March 31, 2026, the Company had no related party payroll taxes payable, compared to $1,279 as of December 31, 2025.
• As of March 31, 2026, the Company had accounts payable of $70 to Shore Accountants MD Inc., an accounting firm wholly owned by the CFO, Christopher Acevedo.

Stakeholder Impact

• Shareholders: The increased net loss and ongoing going concern uncertainty may negatively impact share price. However, positive clinical trial data and upcoming regulatory milestones offer potential upside.
• Employees: Continued R&D investment and potential regulatory approvals could lead to future growth and opportunities. However, the going concern issue may create uncertainty.
• Creditors: The company has significant accounts payable and accrued expenses, and convertible notes, indicating a reliance on debt financing. The ability to meet obligations depends on future financing.
• Suppliers: Increased R&D spending implies continued engagement with vendors and CROs, with significant outstanding payables noted.

Next Steps

• Submit clinical Biologics License Application (BLA) module following an expected Type B meeting with the FDA in Q2 2026.
• Complete conditional Marketing Authorization Application (MAA) submissions to MHRA and EMA in Q2 2026.
• Release additional biomarker data in Q2 2026.
• Initiate confirmatory clinical studies in Q3 2026.
• Evaluate OST-HER2's potential use in other solid tumors, including breast, esophageal, and lung cancers.
• Investigate clinical indications for OST-tADC platform in Osteosarcoma and other solid tumors.

Key Dates

Recommendation

While OS Therapies shows promising clinical data for OST-HER2 and is advancing towards regulatory submissions, the significant increase in net loss, substantial R&D expenses, and the ongoing going concern uncertainty necessitate a cautious approach. The company's ability to secure further funding is critical. Investors should hold positions while monitoring regulatory progress and financing developments.

Keywords

OS Therapies, OST-HER2, Osteosarcoma, Biopharmaceutical, Clinical Trial, FDA Submission, SEC Filing, Form 10-Q, Net Loss, Research and Development